Weekly Report on Healthcare Industry Financing (20240826): Innovations in Wearables and Vascular Intervention Attract Capital

【Gene Editing CRO】Suzhou Haixing Biotechnology Co., Ltd. is a research and development-oriented technology company specializing in gene editing and cellular biotechnology. Established in 2015, the company has a research and development platform in Suzhou that integrates cell gene editing technology with clinical applications. As an integrated biotechnology enterprise, Suzhou Haixing Biotechnology Co., Ltd. focuses on research and development, services, and products. The facility spans over 1,200 square meters, including a GMP-like cell laboratory covering 500 square meters, a molecular laboratory of 350 square meters, a certified P2 laboratory, and SPF-certified animal facilities. The company currently employs a technical team of more than 50 members. Its core business involves the research and development of products and technical services related to cell gene editing, primarily providing technical services and products for clinical research, cellular gene function studies, and genetic diagnostics to enterprises and academic research institutions.

【Investors】OPM

【Intravascular Shockwave Balloon】Spectrumedics Medical Technology (Shanghai) Co., Ltd. was founded in March 2019 by a returned overseas Chinese who has深耕ed in the cardiovascular device field for many years. It is a medical technology enterprise focusing on combining active technology with cardiovascular minimally invasive interventional therapy. Its first product launched is the Sonico intravascular shock wave balloon catheter system, which was independently developed by the company and has obtained patent authorization. This system mainly targets the treatment of arterial vascular calcification. The core team members have professional backgrounds covering multiple disciplines such as electrical, mechanical, acoustics, bioengineering, and biomaterials. They have in-depth cooperation with well-known medical experts both domestically and internationally and also have an overseas research and development team. The team members are young and full of vitality, possessing innovative awareness and the courage to meet challenges.

【Investors】Jiahong Medical

【Vascular Intervention】Shijie Medical Technology (Guangzhou) Co., Ltd. was established in October 2021. The company is mainly engaged in the research, development, production, and sales of vascular interventional medical device products. Shijie Medical is located in the Huangpu District of Guangzhou, with comprehensive R&D, production, and testing equipment for vascular interventional medical devices. It also has a matching 10,000-grade clean production workshop, microbiology laboratory, chemical instrument laboratory, physics laboratory, and aging test laboratory.

【Investor】Wuming Investment

【Cardiac Electrophysiology】PULSECARE, founded in July 2021, is a national high-tech enterprise that owns industry-leading multimodal energy platforms and key technologies, including pulsed electric fields, ultrasound, radiofrequency, and plasma. Currently, PULSECARE has developed several innovative cardiovascular treatment medical device products and solutions for indications such as cardiac electrophysiology (atrial fibrillation) and refractory hypertension. Based on the team's over 20 years of research experience, they have overcome multiple critical bottlenecks within the industry, achieving better clinical efficacy and safety. Focusing on medical device innovation in the field of cardiac and pan-vascular treatments, PULSECARE has efficiently developed two globally pioneering therapeutic medical devices. Among them, the world’s first third-generation nanosecond pulsed electric field ablation (nsPFA) product for atrial fibrillation treatment has successfully completed its registration clinical trial with excellent clinical data. Another groundbreaking innovation is the world’s first adjustable ultrasound renal artery denervation system (muRDN), which is currently in the clinical trial stage. The team has developed four industry-leading multimodal energy platforms, including ultrasound and plasma. Based on advanced multimodal energy platform technology, the company has designed products tailored to different indications and clinical needs, such as nsPFA cardiac electrophysiology ablation, iUltrasound RDN, and multimodal tumor ablation systems.

【Investor】Tasly Capital, Delian Capital, Tianfeng Capital

【AI + New Drug Research and Development】Wukang Biotech is an AI biotechnology service provider dedicated to combining AI biotechnology with automated experimental equipment to empower traditional biopharmaceutical R&D, increase the success rate of R&D, lower the R&D threshold, and shorten the R&D cycle.

【Investor】Ningbo Angel Guidance Fund

【Smart Wearable Devices】Guangdong Jiuzhi Technology Co., Ltd. was established in July 2021. It is a cutting-edge technology company jointly founded by world-class scientists, Yangtze River Scholars, and doctors from China and abroad. The company has research and development centers in Zhongshan and Shenzhen, Guangdong Province. Jiuzhi Technology is a health platform company that integrates "hardware + software + services," dedicated to helping users better understand their bodies and build healthy lifestyles. The team possesses core technologies that lead internationally, including low-power biological signal sensing chips, biomedical signal processing, and intelligent health algorithms, all with independent intellectual property rights. They develop disruptive and innovative smart wearable devices, providing users with round-the-clock medical-grade health protection and forward-looking disease risk warnings.

【Investor】Virtu International, Hong Kong X Technology Fund, Clearwater Bay Fund, Future Technology Fund, Brizan Ventures II

【Digital Health Management】Opu Digital HealthcareOpu Digital Healthcare is committed to developing a series of digital solutions primarily focused on health data collection medical devices, continuously exploring and implementing integrated hardware-software联动data collection and providing comprehensive solutions for chronic diseases. After years of research and technological accumulation, the company focuses on creating a high-end digital health management startup project aimed at building a comprehensive service platform in the healthcare industry. It enjoys a strong reputation in the fields of digital healthcare hardware-software integration, chronic disease management, and sub-health management, with quality channels covering Shaanxi. By utilizing hardware devices to collect human bioelectric signals, the company demonstrates robust technological R&D capabilities. Relying on Internet+, big data artificial intelligence, privacy computing, blockchain technology, and more, it forms an industrial closed loop for health data collection. Through specific applications, digital sensors, VR, and artificial intelligence (AI) devices, professional medical interventions and personalized care are achieved via remote monitoring and proactive health management.

【Investor】Undisclosed

【Synthetic Biology】Meiliu Bio is a technology company focused on synthetic biology, composed of scientific research talents from Zhejiang University. We are committed to developing and mass-producing bio-products with large-scale production capabilities. We have successfully synthesized more than 50 diversified products, covering five major fields: consumer goods, materials, pharmaceuticals, agriculture, and industry. Through innovative technology, we create a better life for people and contribute to social development. We are leading in technology in China, possessing advanced chassis cells, gene component libraries, and various gene-editing tools. By optimizing metabolic pathways, constructing engineered strains, and achieving rapid mass production in a digital industrial production system, we aim for the goals of low energy consumption, low pollution, and low carbon emissions.

【Investor】Sichuan Rongle Investment, West Lake Sci-Tech Innovation Investment